Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952024 · ClinicalTrials.gov registry record · Phase 2

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
20
Study locations

NCT05952024 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 80 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952024, a Phase 2 study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • BIOLOGICAL Rituximab
  • DRUG Acalabrutinib

Study Locations (20)

Brasilia

  • Research Site - Distrito Federal
  • Research Site - Distrito Federal
  • Research Site - Distrito Federal

California

  • Research Site - La Jolla
  • Research Site - Orange

Maryland

  • Research Site - Baltimore
  • Research Site - Rockville

Washington

  • Research Site - Olympia
  • Research Site - Tacoma

Florida

  • Research Site - Jacksonville

Iowa

  • Research Site - Waukee

Michigan

  • Research Site - Detroit

Texas

  • Research Site - Lubbock

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-07-16
Est. Completion 2027-08-24
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05952024

The ClinicalTrials.gov registry entry for NCT05952024 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (63% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.

NCT05952024 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Brasilia, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT05952024 about?

NCT05952024 is a clinical study titled "Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL". The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

What is the current status of trial NCT05952024?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-07-16. Estimated completion is 2027-08-24.

What conditions does trial NCT05952024 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT05952024?

The interventions under investigation include: Rituximab (BIOLOGICAL), Acalabrutinib (DRUG).

Who is sponsoring clinical trial NCT05952024?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952024 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.